328919-26-2

Upstream product

• 4124-41-8 p-toluenesulfonylanhydride 
• 328919-25-1 2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 328918-94-1 2-(3-bromophenyl)-4-(chloromethyl)-5-methyloxazole 
• 328918-96-3 [2-(3-Bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-97-4 2-[2-(3-bromophenyl)-5-methyl-oxazol-4-yl]ethanol 
• 328918-95-2 2-(3-Bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-93-0 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide 

Downstream Products

• 853260-14-7 3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ethyl ester 
• 401468-74-4 3-{4-[2-(2-Biphenyl-3-yl-5-methyloxazol-4-yl)ethoxy]-3-methoxyphenyl}-2-methyl-2-phenoxypropionic acid 
• 401468-87-9 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-naphthalen-1-yl}-2-methyl-2-phenoxypropionic acid 
• 401469-45-2 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(3-methoxy-phenoxy)-2-methyl-propionic acid 
• 401469-50-9 2-(Benzo[1,3]dioxol-5-yloxy)-3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-propionic acid 
• 401469-33-8 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)ethoxy]-phenyl}-2-(3,4-difluoro-phenoxy)-2-methyl-propionic acid 
• 401468-97-1 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(3-fluoro-phenoxy)-2-methyl-propionic acid 
• 401469-25-8 2-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-benzyl}-2-phenoxy-butyric acid 
• 401469-15-6 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(3,4-dimethyl-phenoxy)-2-methyl-propionic acid 
• 401469-07-6 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-chloro-phenoxy)-2-methyl-propionic acid 
• 401469-13-4 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-cyclohexyl-phenoxy)-2-methyl-propionic acid 
• 401468-80-2 3-(4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-3-propyl-phenyl}-2-methyl-2-phenoxy-propionic acid ethyl ester 
• 328919-27-3 2-{3-[2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethoxy]phenoxy}-2-methylpropionic acid ethyl ester 
• 328919-85-3 2-{4-[2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)-ethoxy]-naphthalen-1-yloxy}-2-methyl-propionic acid ethyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.